ACP-105

I’ll be honest — when I first came across ACP-105, I almost dismissed it as another obscure SARM that the bodybuilding forums had latched onto. Another three-letter compound with big promises and thin evidence. But then I dug into the actual research and found something I didn’t expect: this isn’t just a muscle compound. It crosses the blood-brain barrier at nearly three times plasma concentration and has been studied — in mice, let’s be clear — for Alzheimer’s disease and radiation-induced cognitive damage.

That got my attention. And if you’re here because your interest in ACP-105 goes beyond just the gym, this guide is going to give you the honest picture — what the science actually says, where the gaps are, and whether it’s worth your time and money.

The Short Version: ACP-105 is an investigational SARM with unusually high brain penetration and limited but intriguing preclinical research in neuroprotection. There are zero human clinical trials. The cognitive angle is genuinely interesting, but the evidence is thin — a handful of animal studies and computational models. If you’re considering it, go in with open eyes and realistic expectations.

What Is ACP-105?

ACP-105 is a non-steroidal selective androgen receptor modulator — a SARM — developed by ACADIA Pharmaceuticals in the mid-2000s. It was nominated as a development candidate in February 2006 after emerging from a high-throughput screening campaign, and the foundational chemistry paper was published in 2009 in the Journal of Medicinal Chemistry.

Here’s the important context most SARM articles skip: ACP-105 never made it to human clinical trials. ACADIA presented preclinical data at the Experimental Biology 2008 Meeting, and then… nothing. The compound appears to have been shelved. It’s not FDA-approved for any indication, and since 2008, it’s been on the World Anti-Doping Agency’s prohibited list under “other anabolic agents.”

So why are people still talking about it? Two reasons. First, it occupies a unique position in the SARM landscape — a partial agonist with moderate potency, which theoretically means milder suppression than heavier hitters like RAD-140 or LGD-4033. Second, and more interesting from a nootropics perspective, it has remarkably high brain penetration. Most SARMs were designed to target muscle and bone. ACP-105 concentrates in brain tissue at nearly three times the level found in blood plasma.

That brain penetration is what separates ACP-105 from the rest of the SARM conversation — and it’s what makes it relevant to anyone interested in cognitive optimization, not just body composition.

How Does ACP-105 Work?

Think of androgen receptors like locks scattered throughout your body — in your muscles, bones, brain, prostate, and skin. Testosterone is the master key that opens all of them equally. ACP-105 is more like a selective key that turns some of those locks partially while barely touching others.

Technically, ACP-105 is a partial agonist at the androgen receptor. It binds with nanomolar-level potency (a pEC₅₀ of 9.0, for the pharmacology nerds) but doesn’t crank the receptor to full activation the way testosterone or DHT would. When it binds, it induces a specific conformational change in the receptor’s ligand-binding domain that selectively recruits certain transcriptional co-activators — proteins that turn on gene expression in muscle and bone tissue — while largely leaving prostate and other androgen-sensitive tissues alone.

In plain English: it activates the “build muscle and strengthen bones” switches without flipping the “grow your prostate” or “lose your hair” switches as aggressively. That’s the whole premise of selective androgen receptor modulators.

But here’s where ACP-105 gets genuinely interesting for the brain optimization crowd. Its brain-to-plasma ratio is 2.7 — meaning for every unit of ACP-105 circulating in your blood, nearly three units are concentrated in your brain tissue. That’s uncommon for SARMs, and it’s the reason researchers specifically chose this compound for cognitive studies.

Pro Tip: The brain penetration factor is what distinguishes ACP-105 from most other SARMs in the nootropic conversation. If your primary interest is muscle-building, compounds like Ostarine or LGD-4033 have more robust evidence. If the cognitive angle intrigues you, ACP-105 is one of the only SARMs with published neuroprotection data.

ACP-105 is metabolized primarily through CYP3A4 (handling 82-100% of its breakdown), which is important to know because anything that inhibits or induces that enzyme — grapefruit juice, certain medications, even St. John’s Wort — can significantly alter how much active compound ends up in your system.

What ACP-105 Actually Does to Your Brain (And Your Body)

Let me be brutally honest about the evidence here. We’re working with three relevant animal studies and some computational toxicology work. That’s it. No human trials. No large-scale replications. I’m going to walk through what exists, but I want you calibrating your expectations accordingly.

Neuroprotection from Radiation Damage

A 2011 study published in Brain Research (Dayger et al.) exposed female mice to whole-brain irradiation — a model for the cognitive damage that cancer patients often experience from radiation therapy. Mice treated with ACP-105 maintained their sensorimotor function on the rotarod test (basically a balance and coordination challenge), while untreated irradiated mice declined. More interesting: ACP-105 also enhanced cued fear conditioning in both irradiated and non-irradiated mice, suggesting a cognitive benefit that wasn’t just about damage prevention.

Alzheimer’s Disease Model

This is the study that catches most people’s attention. In 2013, George et al. published work in ACS Chemical Neuroscience using triple-transgenic Alzheimer’s disease mice — animals genetically engineered to develop amyloid plaques and cognitive decline. ACP-105 alone reduced anxiety-like behavior in these mice. But the real fireworks came when ACP-105 was combined with AC-186, a selective estrogen receptor beta agonist. Together, they increased the brain’s amyloid-β degrading enzymes, reduced amyloid-β levels, and improved spatial memory on the Morris water maze.

Muscle and Bone Anabolic Effects

The original 2009 characterization study showed ACP-105 improved anabolic parameters in castrated male rats over two weeks — increased muscle and bone markers with less prostate stimulation than testosterone propionate. Standard SARM fare, but confirmatory for its tissue selectivity.

Reality Check: Three animal studies do not make a proven nootropic. The Alzheimer’s data is genuinely intriguing — especially the combination approach with an estrogen receptor agonist — but mice are not people. Compounds that look promising in rodent models fail in human trials more often than they succeed. Treat this as “interesting early science,” not “proven brain enhancer.”

How to Take ACP-105 Without Wasting Your Money

I need to start with the disclaimer that no dosage has been established through human clinical trials. Everything below comes from preclinical pharmacokinetic data and anecdotal user reports. Proceed at your own risk and ideally under the guidance of a healthcare provider.

Dosage ranges (anecdotal):

• Starting dose: 5 mg/day — this is where most people begin to assess tolerance
• Common dose: 10 mg/day — the most frequently reported “sweet spot”
• Upper range: 15–20 mg/day — used by experienced SARM users, with proportionally more suppression risk

Timing matters with this one. ACP-105 has an estimated half-life of 4–6 hours based on human hepatocyte studies, which is short compared to something like LGD-4033. Many users split their dose into two administrations — morning and early afternoon — to maintain more stable blood levels throughout the day.

Forms available:

• Liquid solution (most common — typically in PEG-400 carrier)
• Capsules (less common, pre-dosed)
• Raw powder (requires precise measurement — not recommended for most people)

Cycling protocol (anecdotal):

• 6–8 weeks on (some extend to 12 weeks, but suppression risk increases)
• 4–8 weeks off minimum between cycles
• Post-cycle therapy is generally recommended, especially at higher doses or longer durations

Insider Tip: Oral bioavailability in preclinical models ranged from 38% in rats to 56% in dogs. That means a significant portion of what you take never reaches your bloodstream. Taking ACP-105 on an empty stomach may improve absorption, though this hasn’t been formally studied. Start low, be consistent, and give it at least 3–4 weeks before judging effects.

The Side Effects Nobody Warns You About

Since there are no human clinical trials, everything here comes from anecdotal reports and extrapolation from preclinical data. That itself is the biggest safety concern — you’re essentially an uncontrolled experiment of one.

Commonly reported:

• Mild testosterone suppression — ACP-105 is a partial agonist, so it’s generally considered less suppressive than RAD-140 or LGD-4033, but it still signals your hypothalamus that exogenous androgens are present. Some users report fatigue and decreased libido by weeks 4–6.
• Headaches — particularly in the first few days of use, typically resolving on their own.
• Altered lipid profiles — decreased HDL and increased LDL have been reported, consistent with other SARMs.

Less commonly reported:

• Mild liver enzyme elevation, particularly with cycles exceeding 8 weeks
• Nausea, typically at higher doses

What the computational models flagged: A 2025 in silico toxicological study predicted low endocrine disruption risk (ACP-105 doesn’t appear to aromatize to estrogen), but flagged potential for DNA/protein interactions and possible cyanide release from its nitrile group. These are computational predictions, not confirmed in living organisms — but they’re worth noting.

Important: ACP-105 is not approved for human use by any regulatory agency. It should be avoided entirely by pregnant or nursing women, individuals with liver disease, adolescents, anyone on hormone therapy, and anyone with hormone-sensitive cancers. If you’re taking medications metabolized by CYP3A4 — which includes a huge number of common drugs — consult a healthcare provider before even considering this compound.

Drug interactions to watch:

• CYP3A4 inhibitors (ketoconazole, ritonavir, grapefruit juice, clarithromycin) could dangerously increase ACP-105 levels
• CYP3A4 inducers (rifampin, carbamazepine, St. John’s Wort) could reduce its effectiveness
• Stacking with other suppressive SARMs compounds the hormonal impact

Stacking ACP-105

The One Combination With Actual Research Behind It

The ACP-105 + AC-186 (a selective ERβ agonist) combination is the only stack with published scientific data. In the 2013 Alzheimer’s mouse study, this pairing produced synergistic effects — increased amyloid-β degrading enzymes, reduced brain amyloid-β, and improved spatial memory beyond what either compound achieved individually. It also upregulated androgen receptor expression in the brain, something neither ACP-105 nor DHT accomplished alone.

The practical problem? AC-186 is even more obscure than ACP-105 and essentially unavailable to consumers.

Anecdotal Stacks (No Clinical Evidence)

• ACP-105 + Cardarine (GW-501516): A popular pairing because Cardarine isn’t a SARM and doesn’t suppress testosterone. Users report combining ACP-105’s anabolic effects with Cardarine’s endurance and fat oxidation benefits.
• ACP-105 + MK-677 (Ibutamoren): Some users combine for growth hormone axis stimulation alongside androgen receptor activation. MK-677 also doesn’t suppress testosterone directly.
• ACP-105 + Ostarine: Sometimes stacked for body recomposition, but both compounds cause some degree of suppression — use caution.

What to Avoid

Don’t stack ACP-105 with multiple suppressive SARMs at high doses. Running ACP-105 alongside RAD-140 and LGD-4033 simultaneously is a recipe for significant testosterone suppression that will likely require aggressive post-cycle therapy. Similarly, avoid combining with hepatotoxic compounds — oral anabolic steroids or other liver-stressing substances.

From a cognitive optimization standpoint, pairing with well-researched nootropics like Lion’s Mane or Bacopa Monnieri is theoretically reasonable — they work through entirely different mechanisms — but there’s zero data on these specific combinations.

My Take

Here’s where I’ll be straight with you. ACP-105 is one of the most intellectually interesting SARMs I’ve come across, and simultaneously one of the hardest to recommend.

The brain penetration data is genuinely unusual. Most SARMs were designed to avoid the CNS — ACP-105 actively concentrates there. The Alzheimer’s mouse data, particularly the combination study showing reduced amyloid-β and improved memory, is the kind of early finding that makes a researcher lean forward in their chair. If this compound had continued through development and into human trials, we might be having a very different conversation.

But it didn’t. And we’re not.

What we have is three animal studies, some computational toxicology, and a whole lot of anecdotal reports from bodybuilding forums. That’s a thin foundation for putting an unregulated research chemical into your body. The quality control issues alone should give anyone pause — SARM products are frequently mislabeled, contaminated, or incorrectly dosed.

Who might this be worth exploring for? Someone who has already optimized their foundational health — sleep, gut, stress, nutrition — and is genuinely interested in the cognitive angle specifically, has done thorough due diligence on sourcing and third-party testing, and accepts the reality that they’re essentially running an n=1 experiment with an investigational compound.

Who should look elsewhere? If you’re primarily interested in muscle-building, Ostarine has dramatically more evidence behind it, including actual human trials. If you want neuroprotection, well-studied options like Lion’s Mane, Bacopa Monnieri, or even Creatine offer meaningful cognitive benefits with actual safety data and no hormonal suppression.

The honest assessment: ACP-105 is a fascinating research compound trapped in scientific limbo. The early data hints at something genuinely promising for brain health — but hints aren’t proof, and animal studies aren’t human outcomes. If ACADIA or another group ever picks this back up for clinical development, I’ll be watching closely. Until then, I’d rather stack my cognitive optimization efforts with compounds that have stronger evidence and known safety profiles.

Your brain deserves better than a coin flip.